Months after launching with lofty goal, Flagship startup streamlines ops, chops headcount
Even by Flagship Pioneering’s standards, the stated goal at Vesalius Therapeutics — unveiled at its launch this March — was exceedingly ambitious. Armed with $75 million in Series A funding, the startup was out to “revolutionize the treatment of the diseases that drive ninety percent of human illness.” It would, as CEO Christopher Austin explained, deploy cutting-edge technology to look for underlying causes for a dizzying array of common diseases.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.